Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew Clarke

Showing results (51-60 of 67) with videos related to

Pageof 7
Sort By:
Clinical and Translational Radiation Oncology|December 1, 2022
TORPEdO: A phase III trial of intensity-modulated proton beam therapy versus intensity-modulated radiotherapy for multi-toxicity reduction in oropharyngeal cancerDavid J Thomson, Clare Cruickshank, Helen Baines, et al.
Cancer Discovery|April 29, 2017
Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP InhibitionJane Goodall, Joaquin Mateo, Wei Yuan, et al.
European Journal of Cancer (Oxford, England : 1990)|September 24, 2019
A tailored molecular profiling programme for children with cancer to identify clinically actionable genetic alterationsSally L George, Elisa Izquierdo, James Campbell, et al.
Nature Medicine|July 4, 2018
Functional diversity and cooperativity between subclonal populations of pediatric glioblastoma and diffuse intrinsic pontine glioma cellsMara Vinci, Anna Burford, Valeria Molinari, et al.
The Lancet. Oncology|December 7, 2019
Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trialJoaquin Mateo, Nuria Porta, Diletta Bianchini, et al.
Science Translational Medicine|October 9, 2024
A proinflammatory stem cell niche drives myelofibrosis through a targetable galectin-1 axisRong Li, Michela Colombo, Guanlin Wang, et al.
Cancer Discovery|November 5, 2021
DIPG Harbors Alterations Targetable by MEK Inhibitors, with Acquired Resistance Mechanisms Overcome by Combinatorial InhibitionElisa Izquierdo, Diana M Carvalho, Alan Mackay, et al.
Cancer Research|November 10, 2021
HER3 Is an Actionable Target in Advanced Prostate CancerVeronica Gil, Susana Miranda, Ruth Riisnaes, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 10, 2025
The spectrum of IDH- and H3-wildtype high-grade glioma subgroups occurring across teenage and young adult patient populationsRita Pereira, Alan Mackay, Yura Grabovska, et al.
Neuro-Oncology Advances|March 30, 2026
Characterization of patient-derived site-specific <i>in vivo</i> models of pediatric-type diffuse high-grade glioma using magnetic resonance imagingJessica K R Boult, Diana M Carvalho, Ketty Kessler, et al.
Pageof 7

Showing results (51-60 of 67) with videos related to

Sort By:
Pageof 7
Clinical and Translational Radiation Oncology|December 1, 2022
TORPEdO: A phase III trial of intensity-modulated proton beam therapy versus intensity-modulated radiotherapy for multi-toxicity reduction in oropharyngeal cancerDavid J Thomson, Clare Cruickshank, Helen Baines, et al.
Cancer Discovery|April 29, 2017
Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP InhibitionJane Goodall, Joaquin Mateo, Wei Yuan, et al.
European Journal of Cancer (Oxford, England : 1990)|September 24, 2019
A tailored molecular profiling programme for children with cancer to identify clinically actionable genetic alterationsSally L George, Elisa Izquierdo, James Campbell, et al.
Nature Medicine|July 4, 2018
Functional diversity and cooperativity between subclonal populations of pediatric glioblastoma and diffuse intrinsic pontine glioma cellsMara Vinci, Anna Burford, Valeria Molinari, et al.
The Lancet. Oncology|December 7, 2019
Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trialJoaquin Mateo, Nuria Porta, Diletta Bianchini, et al.
Science Translational Medicine|October 9, 2024
A proinflammatory stem cell niche drives myelofibrosis through a targetable galectin-1 axisRong Li, Michela Colombo, Guanlin Wang, et al.
Cancer Discovery|November 5, 2021
DIPG Harbors Alterations Targetable by MEK Inhibitors, with Acquired Resistance Mechanisms Overcome by Combinatorial InhibitionElisa Izquierdo, Diana M Carvalho, Alan Mackay, et al.
Cancer Research|November 10, 2021
HER3 Is an Actionable Target in Advanced Prostate CancerVeronica Gil, Susana Miranda, Ruth Riisnaes, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 10, 2025
The spectrum of IDH- and H3-wildtype high-grade glioma subgroups occurring across teenage and young adult patient populationsRita Pereira, Alan Mackay, Yura Grabovska, et al.
Neuro-Oncology Advances|March 30, 2026
Characterization of patient-derived site-specific <i>in vivo</i> models of pediatric-type diffuse high-grade glioma using magnetic resonance imagingJessica K R Boult, Diana M Carvalho, Ketty Kessler, et al.
Pageof 7